Varian Medical Systems, Inc.

Varian Medical Systems, Inc., a Palo Alto, California-based foreign-owned subsidiary of Siemens AG, supplies radiation therapy and oncology equipment, treatment planning software, and maintenance services to federal healthcare agencies as a prime contractor (100% of recent awards). The company competes full-and-open across its federal footprint and holds no SBA set-aside certifications. Varian operates as a large business without socioeconomic designations, reflecting its specialized status as a medical device manufacturer whose proprietary systems frequently support sole-source procurements.

Varian's capability portfolio centers on radiation oncology infrastructure: medical linear accelerators (TrueBeam, Edge, Halcyon, Ethos, Trilogy systems), oncology information systems (ARIA), treatment planning software (Eclipse, Mobius, DoseLab), imaging and guidance systems (Calypso), and comprehensive maintenance, parts, and software support. Representative work includes a $4.96 million purchase order from Veterans Integrated Service Network 22 for linear accelerator system maintenance through July 2031, a $6.29 million delivery order from the VA National Acquisition Center for an RT-LINAC system at Michael E. DeBakey VA Medical Center (ultimate completion July 2027), a $2.76 million definitive contract from the VA Technology Acquisition Center for full-scale on-premise application hosting and maintenance through June 2031, a $7.52 million Defense Health Agency contract for linear accelerator maintenance at Naval Medical Center Portsmouth and Keesler Medical Center through April 2031, and a $5.18 million purchase order from Veterans Integrated Service Network 20 for TrueBeam maintenance at the VA Puget Sound Healthcare System through October 2030.

Customer concentration is heavily weighted toward the Department of Veterans Affairs, which anchors the vendor's federal footprint. Veterans Integrated Service Network 12 leads by potential value (113 awards, $876.6 million combined), followed by Defense Logistics Agency Troop Support Medical (42 awards, $517.1 million), the VA National Acquisition Center (122 awards, $263.3 million), Veterans Integrated Service Network 22 (39 awards, $48.4 million), and the Defense Health Agency (54 awards, $45 million). Together, these five customers account for approximately 80% of combined potential value across Varian's federal portfolio. Within the VA customer base, the split between facility-level VISNs (which drive procurement volume and dollars for equipment and maintenance) and the National Acquisition Center (which manages enterprise-wide procurements) reflects a mature, distributed relationship spanning cancer treatment infrastructure modernization across the entire veteran healthcare system. The top three DoD customers—the Navy, Air Force, and Army—drive significant award volume (603, 578, and 443 awards respectively) but generally at lower individual ceiling values tied to spare parts, repairs, and specialized maintenance.

Varian holds multiple large IDVs anchoring its federal business. The VA NAC Radiation Therapy Equipment Systems and Accessories IDIQ ($300 million, effective through September 2035, single-award to Varian via Medical Supply Chain) and the VA NAC Radiation Therapy Next Generation Program ($90 million, single-award through September 2035) are the cornerstone vehicles. Under these contracts, Varian issues delivery orders for linear accelerators, upgrades, software licensing, and maintenance across VA medical centers nationwide. A $300 million single-award IDC with the Defense Logistics Agency for radiation therapy systems and accessories (ultimate completion September 2035) supplies both VA and DLA facilities. The Defense Health Agency's single-award $22 million capital equipment IDC (through September 2025, but with renewal potential) and multiple facility-specific BPAs with individual VISNs enable direct procurement of specialized equipment without additional competitive action. The Indefinite Delivery Contract V797P6077B (119 task orders, $120.7 million), Basic Ordering Agreement N0010485GA003 (110 task orders), and Basic Ordering Agreement N0010478GA012 (106 task orders) represent Navy and Air Force ordering vehicles. This vehicle position reflects Varian's role as the entrenched primary supplier of proprietary radiation therapy infrastructure across federal healthcare.

Activity has grown year over year in awards-per-year (61 in 2022, 43 in 2023, 72 in 2024, 60 in 2025), with 16 awards captured in the first half of 2026. Fifty-seven awards (combined potential value $104.3 million) reach ultimate completion within the next twenty-four months, exposing the vendor to near-term recompete risk on equipment maintenance and software support renewals, particularly within the VA's distributed VISN structure. However, the scale and specificity of Varian's equipment portfolio, combined with OEM maintenance requirements, typically result in sole-source recompetes or limited-source awards under FAR 13.106-1(b).

Service Contract Inventory reporting, which captures federal service contracts above the $150,000 threshold, shows SCI-reportable invoiced revenue of $27.7 million across FY2022–FY2024 (FY2022: $171 thousand; FY2023: $9 million; FY2024: $18.6 million). The SCI data reflects an upward FTE trajectory (0.1 FTEs in FY2022 to 5.3 FTEs in FY2024) and growing labor hours, indicating expanding on-site service delivery. Median government-paid hourly rates on SCI-reportable work run around $1,562/hr, with the 90th percentile at $12,397/hr, reflecting a mix of routine technician labor and specialized engineering support. Across SCI-reportable prime contracts, Varian self-performs 100% of contractor hours with zero subcontractor engagement, positioning the vendor as a vertically integrated service provider rather than a labor-arbitrage player.

Varian operates as a prime contractor across its entire federal footprint (100% prime, 0% sub of award count), delivering equipment and services directly to agencies without teaming arrangements or significant subcontractor support on the awards captured in this source. Three grant sub-awards appear in the portfolio: a September 2024 sub-award from the University of Maryland, Baltimore for an extended modular anthropomorphic phantom for imaging and treatment optimization in radiotherapy; a September 2024 sub-award from Dana-Farber Cancer Institute for development of stacked imager technology, scintillator materials, and real-time beam tracking for radiation therapy; and an August 2024 sub-award from the University of Maryland, Baltimore for three-dimensional prompt gamma imaging for online proton beam dose verification. These indicate Varian's participation in federally funded research advancing radiation therapy instrumentation and technique, likely under National Institutes of Health grants, though the source does not specify grant programs or CFDA numbers.

The vendor's corporate structure includes named subsidiaries Varex Imaging Corp (medical imaging devices), D3 Oncology Inc., and Calypso Medical Technologies, Inc., reflecting Varian's acquisition strategy for expanding radiation oncology and imaging capabilities. These subsidiaries appear in the source as separate legal entities but operate under Varian's federal contracting umbrella.

Varian's federal footprint is characterized by deep specialization in radiation oncology infrastructure, mature sole-source or limited-source relationships with the VA and Defense Health Agency, large equipment delivery orders bundled with multi-year maintenance contracts, and sustained federal investment in cancer treatment modernization across military and veteran healthcare systems. The vendor's foreign ownership and large-business status place it outside SBA set-aside competition but position it as the dominant proprietary supplier in its vertical, with limited domestic competitors and high switching costs for government customers.